side effects of glp 1 drugs for weight loss GLP-1 medication diabetes and Glucagon-like Receptor-1 agonists for obesity:

Cotadutide was subsequently studied at doses ranging from 100 to 300 mg once daily in overweight or obese subjects with T2D

Prucalopride: the evidence for its use in the treatment of chronic constipation

Abstract Glucose-dependent insulinotropic polypeptide (GIP) is secreted by enteroendocrine K cells, primarily located in the upper small intestine, in response to food intake and plays a significant role in the postprandial regulation of nutrient metabolism

In terms of constipation, 7 studies (with 331 and 279 subjects from the experimental and control groups, respectively) were included for analysis

Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease

Third -- and most relevant to the GLP-1 conversation -- some olive-derived compounds appear to stimulate the very same gut hormone pathways that GLP-1 drugs target pharmacologically